Diazyme announces partnership with Maccura for COVID-19 test, also launches FDA EUA

Aug. 4, 2020

Diazyme Laboratories has announced a partnership with Maccura Biotechnology (USA) LLC, as well as the launch of its SARS-COV-2 RT-PCR diagnostics test, which has received emergency use authorization (EUA) from the U.S. Food and Drug Administration, according to a release from Diazyme.

“Here at Diazyme, we continue to address gaps in testing during the COVID-19 public health emergency. The SARS-CoV-2 Fluorescent PCR Kit- Maccura Biotechnology (USA) is a RT-PCR test intended for the qualitative detection of SARS-CoV-2 viral nucleic acids in upper respiratory specimens (e.g., oropharyngeal swabs, nasopharyngeal swabs, nasal swabs, and mid-turbinate swabs) from individuals suspected of COVID-19. The demand for molecular diagnostic tests continues to outpace availability and wait times are getting too long to be meaningful in quarantine situations. We are pleased to announce our partnership with Maccura, bringing more test capacity to clinical laboratories", said Chong Yuan, PhD, Managing Director of Diazyme Laboratories.

Jinson Xu, the General Manager of Maccura Biotechnology (USA) LLC, said, “Maccura Biotechnology (USA) is pleased to enter into a partnership with Diazyme Laboratories providing additional testing capacity during the public health emergency in the USA. We have a long business relationship with Diazyme and continue to work together in many areas globally.”  

Visit Diazyme for more news

ID 18314167 © Petrina Calabalic | Dreamstime.com
dreamstime_xxl_18314167
ID 176472934 © Grafner | Dreamstime.com
dreamstime_xxl_176472934
ID 265869013 © Iakov Filimonov | Dreamstime.com
dreamstime_xxl_265869013
By Watercolor_Kawaii on Adobe Stock
adobestock_1175800153